![](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/03\/Susan-Fitzpatrick-Napier-Founder-TrialWire-photo-2-1.jpg\"\/)
<\/p>\nThe bru\u00adtal truth is 80% of clin\u00adi\u00adcal tri\u00adals face en\u00adroll\u00adment de\u00adlays. Near\u00adly 90% miss re\u00adcruit\u00adment tar\u00adgets. In on\u00adcol\u00ado\u00adgy, CNS and rare dis\u00adease tri\u00adals, where pro\u00adto\u00adcols are com\u00adplex and el\u00adi\u00adgi\u00adble pa\u00adtients nar\u00adrow\u00adly de\u00adfined, those de\u00adlays are am\u00adpli\u00adfied by in\u00adtense com\u00adpe\u00adti\u00adtion with de\u00adlays cost\u00ading up\u00adward of $50,000 per day.<\/p>\n
And yet most spon\u00adsors still treat re\u00adcruit\u00adment as an af\u00adter\u00adthought\u2014a \u201ccam\u00adpaign\u201d to launch af\u00adter sites are ac\u00adti\u00advat\u00aded, when the clock is al\u00adready tick\u00ading.<\/p>\n
The biotechs win\u00adning in 2026 are build\u00ading AI-first re\u00adcruit\u00adment en\u00adgines in\u00adto their de\u00advel\u00adop\u00adment pro\u00adgrams from day ze\u00adro. Not as a nice-to-have. But as in\u00adfra\u00adstruc\u00adture.<\/p>\n
From Re\u00adac\u00adtive Cam\u00adpaigns to Al\u00adways-On En\u00adgines<\/p>\n
The old play\u00adbook: Ac\u00adti\u00advate sites. Wait. Hope pa\u00adtients show up. Pan\u00adic when they don\u2019t. Scram\u00adble for res\u00adcue so\u00adlu\u00adtions 8\u201312 weeks lat\u00ader.<\/p>\n
The new stan\u00addard: AI-dri\u00adven, al\u00adways-on en\u00adroll\u00adment en\u00adgines that con\u00adtin\u00adu\u00adous\u00adly find, match, and pre-screen pa\u00adtients\u2014start\u00ading in un\u00adder 24 hours.<\/p>\n
The Cost of Wait\u00ading<\/p>\n
Tufts CS\u00adDD da\u00adta is un\u00adfor\u00adgiv\u00ading:\n<\/p>\n
37% of sites un\u00adder-en\u00adroll
\n11% en\u00adroll ze\u00adro pa\u00adtients
\nOn\u00adly 47% of stud\u00adies com\u00adplete en\u00adroll\u00adment on time
\nOne in six stud\u00adies takes 2x longer than planned<\/p>\n
In on\u00adcol\u00ado\u00adgy and CNS es\u00adpe\u00adcial\u00adly, com\u00adpe\u00adti\u00adtion for pa\u00adtients is fierce, those de\u00adlays are com\u00adpound\u00aded by bio\u00admark\u00ader re\u00adquire\u00adments, pri\u00ador ther\u00ada\u00adpy lines, co\u00admor\u00adbidi\u00adties, and dis\u00adease stag\u00ading.\n<\/p>\n
Biotechs can\u2019t af\u00adford to wait 8 weeks to re\u00adal\u00adize a site isn\u2019t de\u00adliv\u00ader\u00ading. They need re\u00adal-time in\u00adtel\u00adli\u00adgence and guar\u00adan\u00adteed re\u00adsponse speed.\n<\/p>\n
At JPM this year, the mes\u00adsage was blunt: the fu\u00adture is AI-first en\u00adroll\u00adment, not just last-minute dig\u00adi\u00adtal res\u00adcue. With Phase III tri\u00adal de\u00adlays cost\u00ading spon\u00adsors up\u00adward of $50,000 per day, the stakes are clear.\n<\/p>\n
\u201cBiotechs that build AI-en\u00adabled re\u00adcruit\u00adment in\u00adto de\u00advel\u00adop\u00adment now will se\u00adcure faster, more pre\u00addictable time\u00adlines. Those that don\u2019t will be left scram\u00adbling for last-minute \u2018res\u00adcues\u2019 when mile\u00adstones slip.\u201d\n<\/p>\n
Su\u00adsan Fitz\u00adpatrick-Napi\u00ader, CEO & Founder, Tri\u00adal\u00adWire<\/p>\n
<\/p>\n
In on\u00adcol\u00ado\u00adgy and CNS, that means dy\u00adnam\u00adi\u00adcal\u00adly iden\u00adti\u00adfy\u00ading high\u00adly spe\u00adcif\u00adic sub\u00adpop\u00adu\u00adla\u00adtions \u2014 then screen\u00ading for bio\u00admark\u00ader sta\u00adtus, pri\u00ador lines of ther\u00ada\u00adpy, co\u00admor\u00adbidi\u00adties, con\u00adcomi\u00adtant med\u00adica\u00adtions or CNS dis\u00adease stage \u2014 rather than re\u00adly\u00ading on\u00adly on pa\u00adtients that sites al\u00adready know.\n<\/p>\n
Tri\u00adal\u00adWire was de\u00adsigned for this en\u00advi\u00adron\u00adment: an AI-dri\u00adven en\u00adgine built for speed to sup\u00adport com\u00adplex, late-stage stud\u00adies where every month of de\u00adlay com\u00adpounds both cost and com\u00adpet\u00adi\u00adtive risk. The plat\u00adform, built on Sales\u00adforce Health Cloud, en\u00adables spon\u00adsors to reach nar\u00adrow\u00adly de\u00adfined co\u00adhorts at scale with\u00adout over\u00adwhelm\u00ading site staff. With a 24-hour start\u00adup and risk-share pay-per-en\u00adroll\u00adment mod\u00adel, the plat\u00adform is dis\u00adrupt\u00ading the re\u00adcruit\u00adment space around val\u00adue, se\u00adcu\u00adri\u00adty, and re\u00adal-time tri\u00adal trans\u00adparen\u00adcy.\n<\/p>\n
Tri\u00adal\u00adWire ac\u00adti\u00advates in un\u00adder 24 hours and us\u00ades ad\u00advanced al\u00adgo\u00adrithms to find the right pa\u00adtients, AI-screen\u00admatch to de\u00adter\u00admine ex\u00adact el\u00adi\u00adgi\u00adbil\u00adi\u00adty, and a so\u00adphis\u00adti\u00adcat\u00aded da\u00adta and com\u00admu\u00adni\u00adca\u00adtions por\u00adtal of\u00adfer\u00ading pa\u00adtient con\u00adtact tools and man\u00adage\u00adment for sites, and re\u00adal-time trans\u00adpar\u00adent da\u00adta for Spon\u00adsors and CROs. Each study fea\u00adtures its own cus\u00adtomized AI Agent screen\u00ader, trained on el\u00adi\u00adgi\u00adbil\u00adi\u00adty and ex\u00adclu\u00adsion cri\u00adte\u00adria, that con\u00adstant\u00adly learns from thou\u00adsands of pa\u00adtient in\u00adter\u00adac\u00adtions \u2014 in\u00adclud\u00ading health da\u00adta, bio\u00admark\u00aders, and pri\u00ador treat\u00adments \u2014 be\u00adcom\u00ading smarter and more pre\u00adcise with every en\u00adgage\u00adment.\n<\/p>\n
AI-dri\u00adven au\u00adtoma\u00adtion has de\u00adliv\u00adered a 30\u201345% up\u00adlift in el\u00adi\u00adgi\u00adble re\u00adfer\u00adrals ver\u00adsus con\u00adven\u00adtion\u00adal out\u00adreach, while cut\u00adting man\u00adu\u00adal pre-screen\u00ading time at sites by up to 70%. The plat\u00adform\u2019s site-to-re\u00adfer\u00adral com\u00admu\u00adni\u00adca\u00adtions sys\u00adtem rou\u00adtine\u00adly de\u00adliv\u00aders 98% re\u00adsponse rates with me\u00addi\u00adan times around 90 sec\u00adonds.\n<\/p>\n
\u201cFor spon\u00adsors, that com\u00adbi\u00adna\u00adtion trans\u00adlates in\u00adto faster, more pre\u00addictable en\u00adroll\u00adment curves. For sites, it feels like an ex\u00adten\u00adsion of their team rather than an\u00adoth\u00ader sys\u00adtem to man\u00adage,\u201d said Fitz\u00adpatrick-Napi\u00ader.\n<\/p>\n
From Buzz\u00adword to Busi\u00adness In\u00adfra\u00adstruc\u00adture<\/p>\n
The tone on AI in clin\u00adi\u00adcal de\u00advel\u00adop\u00adment has shift\u00aded from vi\u00adsion to ver\u00adi\u00adfi\u00adca\u00adtion. Ses\u00adsions at JPM this year con\u00adverged on a sin\u00adgle idea: in\u00advestors now re\u00adward AI where it\u2019s em\u00adbed\u00added in core clin\u00adi\u00adcal work\u00adflows \u2014 not where it sits as a stand\u00adalone ex\u00adper\u00adi\u00adment.\n<\/p>\n
\u201cAny\u00adthing less shows up as ex\u00ade\u00adcu\u00adtion risk, not in\u00adno\u00adva\u00adtion risk,\u201d said Fitz\u00adpatrick-Napi\u00ader.\n<\/p>\n
Across health\u00adcare in\u00advest\u00adment, the as\u00adsump\u00adtion is that AI in clin\u00adi\u00adcal de\u00advel\u00adop\u00adment is the in\u00adfra\u00adstruc\u00adture lay\u00ader that pow\u00aders scal\u00adable plat\u00adforms, par\u00adtic\u00adu\u00adlar\u00adly in late-stage on\u00adcol\u00ado\u00adgy and CNS, where the bulk of R&D spend and com\u00adpet\u00adi\u00adtive risk now sits.\n<\/p>\n
\u201cTri\u00adal\u00adWire re\u00adflects that shift. It\u2019s built as an in\u00adfra\u00adstruc\u00adture-grade plat\u00adform on top of en\u00adter\u00adprise-lev\u00adel health cloud tech\u00adnol\u00ado\u00adgy, with role-based ac\u00adcess for sites, spon\u00adsors and CROs, and a foot\u00adprint de\u00adsigned to be ac\u00adcept\u00adable to reg\u00adu\u00adla\u00adtors and en\u00adter\u00adprise IT teams,\u201d said Fitz\u00adpatrick-Napi\u00ader.\n<\/p>\n
What Biotech Lead\u00aders Are Ac\u00adtu\u00adal\u00adly Ask\u00ading<\/p>\n
What will AI ac\u00adtu\u00adal\u00adly change for my tri\u00adals?<\/p>\n
AI is mov\u00ading re\u00adcruit\u00adment from re\u00adac\u00adtive bursts to a con\u00adtin\u00adu\u00adous\u00adly learn\u00ading ca\u00adpa\u00adbil\u00adi\u00adty that au\u00adto\u00admates el\u00adi\u00adgi\u00adbil\u00adi\u00adty match\u00ading at scale. In on\u00adcol\u00ado\u00adgy and CNS, that means en\u00adcod\u00ading dis\u00adease-spe\u00adcif\u00adic and bio\u00admark\u00ader log\u00adic di\u00adrect\u00adly in\u00adto match\u00ading al\u00adgo\u00adrithms and us\u00ading re\u00adal-world da\u00adta to sur\u00adface pa\u00adtients who would nev\u00ader ap\u00adpear on a tra\u00addi\u00adtion\u00adal site list.\n<\/p>\n
Near\u00adly half of in\u00adves\u00adtiga\u00adtive sites ei\u00adther un\u00adder-en\u00adroll or en\u00adroll no pa\u00adtients at all, and around 30% of a tri\u00adal\u2019s costs can be tied to en\u00adroll\u00adment ac\u00adtiv\u00adi\u00adties \u2014 mak\u00ading any up\u00adlift in hit rate and pre\u00addictabil\u00adi\u00adty dis\u00adpro\u00adpor\u00adtion\u00adate\u00adly valu\u00adable in high-cost, late-stage pro\u00adgrams.\n<\/p>\n
Is AI-dri\u00adven re\u00adcruit\u00adment ac\u00adcept\u00adable to reg\u00adu\u00adla\u00adtors, sites and pa\u00adtients?<\/p>\n
Reg\u00adu\u00adla\u00adtors glob\u00adal\u00adly are sig\u00adnal\u00ading sup\u00adport for re\u00adspon\u00adsi\u00adble AI use where there\u2019s trans\u00adparen\u00adcy, hu\u00adman over\u00adsight and strong da\u00adta pro\u00adtec\u00adtion. On\u00adcol\u00ado\u00adgy and neu\u00adrol\u00ado\u00adgy cen\u00adters are re\u00adspond\u00ading well to AI-dri\u00adven out\u00adreach when the ex\u00adpe\u00adri\u00adence is fric\u00adtion\u00adless and re\u00adspect\u00adful. For sites, AI au\u00adtoma\u00adtion that cuts pre-screen\u00ading work by 70% frees ca\u00adpac\u00adi\u00adty for pa\u00adtient care and pro\u00adto\u00adcol com\u00adpli\u00adance.\n<\/p>\n
Can we trust AI on bias, da\u00adta qual\u00adi\u00adty and ethics?<\/p>\n
Gov\u00ader\u00adnance has be\u00adcome the re\u00adal bat\u00adtle\u00adground. Tri\u00adal\u00adWire\u2019s ro\u00adbust ar\u00adchi\u00adtec\u00adture on Sales\u00adforce Health Cloud re\u00adsponds di\u00adrect\u00adly to that ex\u00adpec\u00adta\u00adtion. It sep\u00ada\u00adrates iden\u00adti\u00adfi\u00adable pa\u00adtient in\u00adfor\u00adma\u00adtion at the site lev\u00adel from spon\u00adsor- and CRO-fac\u00ading mon\u00adi\u00adtor\u00ading dash\u00adboards, main\u00adtains de\u00adtailed logs of re\u00adcruit\u00adment ac\u00adtiv\u00adi\u00adty, and is de\u00adsigned to meet strin\u00adgent pri\u00adva\u00adcy and se\u00adcu\u00adri\u00adty stan\u00addards.\n<\/p>\n
The Win\u00addow Is Clos\u00ading<\/p>\n
Biotechs that em\u00adbrace AI-first en\u00adroll\u00adment ar\u00adchi\u00adtec\u00adture now aren\u2019t just op\u00adti\u00admiz\u00ading a tac\u00adti\u00adcal prob\u00adlem \u2014 they\u2019re build\u00ading a struc\u00adtur\u00adal ad\u00advan\u00adtage in a mar\u00adket where time\u00adlines, costs and da\u00adta qual\u00adi\u00adty are non-ne\u00adgo\u00adtiable com\u00adpet\u00adi\u00adtive met\u00adrics.\n<\/p>\n
For spon\u00adsors, the cal\u00adcu\u00adlus is straight\u00adfor\u00adward: de\u00adlay AI adop\u00adtion in en\u00adroll\u00adment, and you sig\u00adnal ex\u00ade\u00adcu\u00adtion risk. Em\u00adbed it from day ze\u00adro \u2014 es\u00adpe\u00adcial\u00adly in on\u00adcol\u00ado\u00adgy, CNS and rare dis\u00adeases \u2014 and you own the time\u00adlines and pre\u00addictabil\u00adi\u00adty that in\u00advestors re\u00adward.\n<\/p>\n
Tri\u00adal\u00adWire was built for spon\u00adsors who want a new ap\u00adproach: an AI-pow\u00adered re\u00adcruit\u00adment en\u00adgine that can start or re\u00adboot a stalled tri\u00adal in un\u00adder 24 hours, plug in\u00adto any CRO or de\u00advel\u00adop\u00adment plan, of\u00adfer a risk-share mod\u00adel and open the doors to the pa\u00adtients who need them most.\n<\/p>\n
By 2027, the ques\u00adtion won\u2019t be \u201cshould we use AI in en\u00adroll\u00adment?\u201d It will be: \u201cHow did we ever run tri\u00adals with\u00adout it?\u201d\n<\/p>\n